NCT00736242View on ClinicalTrials.gov

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

CompletedOBSERVATIONAL
Enrollment

232

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Chronic Hepatitis CHepatitis CHIV Infections
Interventions
BIOLOGICAL

PEG-IFN alfa-2b

Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling

DRUG

RBV

Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00736242 - Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) | Biotech Hunter | Biotech Hunter